Elsevier

Vaccine

Volume 31, Supplement 2, 18 April 2013, Pages B61-B72
Vaccine

Review
The estimated mortality impact of vaccinations forecast to be administered during 2011–2020 in 73 countries supported by the GAVI Alliance

https://doi.org/10.1016/j.vaccine.2012.11.035Get rights and content

Abstract

Introduction

From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted by the GAVI Alliance and the Bill & Melinda Gates Foundation to estimate the impact of vaccination in 73 countries supported by the GAVI Alliance.

Methods

The number of deaths averted in persons projected to be vaccinated during 2011–2020 was estimated for ten antigens: hepatitis B, yellow fever, Haemophilus influenzae type B (Hib), Streptococcus pneumoniae, rotavirus, Neisseria meningitidis serogroup A, Japanese encephalitis, human papillomavirus, measles, and rubella. Impact was calculated as the difference in the number of deaths expected over the lifetime of vaccinated cohorts compared to the number of deaths expected in those cohorts with no vaccination. Numbers of persons vaccinated were based on 2011 GAVI Strategic Demand Forecasts with projected dates of vaccine introductions, vaccination coverage, and target population size in each country.

Results

By 2020, nearly all GAVI-supported countries with endemic disease are projected to have introduced hepatitis B, Hib, pneumococcal, rotavirus, rubella, yellow fever, N. meningitidis serogroup A, and Japanese encephalitis-containing vaccines; 55 (75 percent) countries are projected to have introduced human papillomavirus vaccine. Projected use of these vaccines during 2011–2020 is expected to avert an estimated 9.9 million deaths. Routine and supplementary immunization activities with measles vaccine are expected to avert an additional 13.4 million deaths. Estimated numbers of deaths averted per 1000 persons vaccinated were highest for first-dose measles (16.5), human papillomavirus (15.1), and hepatitis B (8.3) vaccination. Approximately 52 percent of the expected deaths averted will be in Africa, 27 percent in Southeast Asia, and 13 percent in the Eastern Mediterranean.

Conclusion

Vaccination of persons during 2011–2020 in 73 GAVI-eligible countries is expected to have substantial public health impact, particularly in Africa and Southeast Asia, two regions with high mortality. The actual impact of vaccination in these countries may be higher than our estimates because several widely used antigens were not included in the analysis. The quality of our estimates is limited by lack of data on underlying disease burden and vaccine effectiveness against fatal disease outcomes in developing countries. We plan to update the estimates annually to reflect updated demand forecasts, to refine model assumptions based on results of new information, and to extend the analysis to include morbidity and economic benefits.

Highlights

► We modeled deaths averted in persons vaccinated in 73 GAVI-eligible countries. ► Projected use of nine antigens during 2011–2020 is expected to avert 10 million deaths. ► Routine and supplemental measles vaccination is expected to avert an additional 13 million deaths. ► Most deaths averted will be in Africa and Southeast Asia, regions with high mortality.

Introduction

In 2008, the GAVI Alliance began work to estimate the impact of vaccination in countries eligible for support. Initial estimates relied on vaccine-specific estimates of the average number of deaths averted per 1000 persons vaccinated in GAVI-eligible countries, multiplied by forecast numbers of persons vaccinated. Estimates of the number of deaths averted per 1000 persons vaccinated were derived from published and unpublished studies, including vaccine trials and modeled impact estimates [1], [2]. While conceptually simple, the utility of this approach was limited because each derived estimate of the number of deaths averted per 1000 persons vaccinated was specific to a specific time period, target population, and vaccination strategy.

In August–December 2011, we updated the impact estimates using more refined modeling approaches, where available, and updated vaccine demand forecasts. Although the primary purpose of this exercise was to estimate the impact of GAVIs vaccine support, mortality in the 73 GAVI-eligible countries accounts for 94 percent of all deaths and 97 percent of deaths in children under five years old projected to occur during 2011–2020 in countries classified by the World Bank as low- or lower–middle-income economies [3]. Thus, the results of our analyses were used as a starting point for work to estimate the impact and economic benefits of the 2011–2020 Global Vaccine Action Plan [4].

This report summarizes the methods used to derive estimates of deaths averted in persons projected to be vaccinated during 2011–2020 in 73 GAVI-supported countries, presents the results of these analyses, and discusses limitations of the estimates, including potential biases. Work to validate key model assumptions and refine the estimates is ongoing. It is anticipated that subsequent analyses will be extended to include additional vaccines, morbidity impacts, and economic benefits.

Section snippets

Methods

The expected number of deaths averted in persons projected to be vaccinated during 2011–2020 in 73 countries supported by the GAVI Alliance was estimated for hepatitis B, yellow fever 17D, conjugate Haemophilus influenzae type B (Hib), conjugate Streptococcus pneumoniae, rotavirus, conjugate N. meningitidis serogroup A, live attenuated Japanese encephalitis, human papillomavirus types 16 and 18, rubella, and measles-containing vaccines. All 73 study countries will be receiving direct financial

Results

The cumulative numbers of countries projected to have introduced hepatitis B, H. influenzae type B (Hib), S. pneumoniae, rotavirus, rubella, human papillomavirus, yellow fever, N. meningitidis serogroup A, second-dose measles, and Japanese encephalitis vaccines are shown by year for the period 2011–2020 in Fig. 1. By 2020, all or nearly all GAVI-eligible countries with endemic disease are projected to have introduced hepatitis B, Hib, pneumococcal, rotavirus, rubella, yellow fever, conjugate N.

Discussion

This study demonstrates that vaccination in 73 GAVI-eligible countries during 2011–2020 is expected to have substantial health impacts, with the largest number of deaths averted occurring in Africa and Southeast Asia, the two regions with the highest mortality burden. Due to time constraints and lack of suitable models, we did not include the impact of all vaccines that are part of existing country immunization programs in these countries, or the impact of all vaccines likely to become

Conflict of interest

The authors confirm that they have no conflict of interest.

References (81)

  • E. Vynnycky et al.

    The predicted impact of private sector MMR vaccination on the burden of congenital rubella syndrome

    Vaccine

    (2003)
  • E. Miller et al.

    Consequences of confirmed maternal rubella at successive stages of pregnancy

    Lancet

    (1982)
  • S. Al-Awaidy et al.

    Costs of congenital rubella syndrome (CRS) in Oman: evidence based on long-term follow-up of 43 children

    Vaccine

    (2006)
  • E. Simons et al.

    Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data

    Lancet

    (2012)
  • D. Sur et al.

    Efficacy and safety of a modified killed whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised double-blind, placebo-controlled trial

    Lancet

    (2009)
  • D.D. Trach et al.

    Field trial of a locally produced, killed, oral cholera vaccine in Vietnam

    Lancet

    (1997)
  • B.D. Gessner et al.

    Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial

    Lancet

    (2005)
  • R.T. Novak et al.

    Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data

    Lancet Infect Dis

    (2012)
  • A. Clark et al.

    Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data

    Lancet

    (2009)
  • L. Liu et al.

    Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000

    Lancet

    (2012)
  • B.G. Williams et al.

    Estimates of world-wide distribution of child deaths from acute respiratory infections

    Lancet Infect Dis

    (2002)
  • B.A. Lopman et al.

    Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006 to 2011

    Curr Opin Virol

    (2012)
  • Applied Strategies

    GAVI vaccine portfolio metrics analysis. Input assumptions – board paper case

  • L.A. Lee

    Forecasting the impact of GAVI Alliance vaccine support using the long range cost and impact model: methods and limitations

    (August 9, 2011)
  • United Nations, Department of Economic and Social Affairs, Population Division

    World population prospects, the 2010 revision

    (2010)
  • Global Vaccine Action Plan

    Vaccine

    (2013)
  • World Health Organization and United Nations Children's Fund

    Immunization summary

    (January 2012)
  • S.T. Goldstein et al.

    A mathematical model to estimate global hepatitis B disease burden and vaccination impact

    Int J Epidemiol

    (2005)
  • W. Winfrey et al.

    Methods used in the Lives Saved Tool (LiST)

    BMC Public Health

    (2011)
  • E. Theodoratou et al.

    The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality

    Int J Epidemiol

    (2010)
  • S.S. Morris et al.

    Predicting the distribution of under-five deaths by cause in countries without adequate vital registration systems

    Int J Epidemiol

    (2003)
  • C. Boschi-Pinto et al.

    Estimating child mortality due to diarrhoea in developing countries

    Bull World Health Organ

    (2008)
  • U.D. Parashar et al.

    Rotavirus and severe childhood diarrhea

    Emerg Infect Dis

    (2006)
  • C.L. Fischer Walker et al.

    Rotavirus vaccine and diarrhea mortality: quantifying regional variation in effect size

    BMC Public Health

    (2011)
  • V. Richardson et al.

    Effect of rotavirus vaccination on death from childhood diarrhea in Mexico

    N Engl J Med

    (2010)
  • G.M. do Carmo et al.

    Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis

    PLoS Med

    (2011)
  • J.J. Kim et al.

    Multiparameter calibration of a natural history model of cervical cancer

    Am J Epidemiol

    (2007)
  • J.J. Kim et al.

    The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting

    Br J Cancer

    (2007)
  • S.J. Goldie et al.

    Cost-effectiveness of cervical cancer screening in five developing countries

    N Engl J Med

    (2005)
  • N.G. Campos et al.

    Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa

    Int J Cancer

    (2012)
  • Cited by (115)

    • Vaccine human clinical trial

      2022, System Vaccinology: The History, the Translational Challenges and the Future
    View all citing articles on Scopus
    1

    Current address: GAVI Alliance, Geneva, Switzerland.

    2

    Current address: Management Sciences for Health, Arlington, VA, United States.

    View full text